PT1143958E - Composição farmacêutica e utilização de rnsaid para o tratamento da inflamação. - Google Patents

Composição farmacêutica e utilização de rnsaid para o tratamento da inflamação. Download PDF

Info

Publication number
PT1143958E
PT1143958E PT99968626T PT99968626T PT1143958E PT 1143958 E PT1143958 E PT 1143958E PT 99968626 T PT99968626 T PT 99968626T PT 99968626 T PT99968626 T PT 99968626T PT 1143958 E PT1143958 E PT 1143958E
Authority
PT
Portugal
Prior art keywords
cox
nsaid
flurbiprofen
nsaids
dose
Prior art date
Application number
PT99968626T
Other languages
English (en)
Portuguese (pt)
Inventor
William J Wechter
Original Assignee
Univ Loma Linda Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22517175&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1143958(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Loma Linda Med filed Critical Univ Loma Linda Med
Publication of PT1143958E publication Critical patent/PT1143958E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4021-aryl substituted, e.g. piretanide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT99968626T 1998-09-03 1999-09-03 Composição farmacêutica e utilização de rnsaid para o tratamento da inflamação. PT1143958E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14639598A 1998-09-03 1998-09-03

Publications (1)

Publication Number Publication Date
PT1143958E true PT1143958E (pt) 2007-04-30

Family

ID=22517175

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99968626T PT1143958E (pt) 1998-09-03 1999-09-03 Composição farmacêutica e utilização de rnsaid para o tratamento da inflamação.

Country Status (13)

Country Link
US (1) US6472433B2 (https=)
EP (1) EP1143958B8 (https=)
JP (1) JP2002524415A (https=)
CN (1) CN1391470A (https=)
AT (1) ATE353010T1 (https=)
AU (1) AU6026099A (https=)
CA (1) CA2342628C (https=)
CY (1) CY1106541T1 (https=)
DE (1) DE69933049T2 (https=)
DK (1) DK1143958T3 (https=)
ES (1) ES2281981T3 (https=)
PT (1) PT1143958E (https=)
WO (1) WO2000013684A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
JP2002533379A (ja) 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
DE19907895A1 (de) * 1999-02-24 2000-11-16 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen bei Mensch und Tier, welche durch die Hemmung der Aktivierung von NF-kB therapeutisch beeinflußt werden können
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
ATE283048T1 (de) 1999-12-08 2004-12-15 Pharmacia Corp Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
DE10047319A1 (de) * 2000-09-25 2002-04-18 Paz Arzneimittelentwicklung Verwendung von R-Arylpropionsäuren zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen, welche durch die Hemmung der Aktivierung des nukleären Transkriptionsfaktors AP-1 therapeutisch beeinflußt werden können
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
US9125899B1 (en) 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
US20150183737A1 (en) * 2012-07-20 2015-07-02 Vanderbilt University Compositions and methods for substrate-selective inhibition of endocannabinoid oxygenation
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
CN113712960B (zh) * 2021-09-23 2023-04-07 南京医科大学 R-酮咯酸在防治主动脉夹层和主动脉瘤中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
IT1298214B1 (it) * 1998-01-28 1999-12-20 Dompe Spa Sali dell'acido (r) 2-(3-benzoilfenil) propionico e loro composizioni farmaceutiche.

Also Published As

Publication number Publication date
DE69933049T2 (de) 2007-10-04
ATE353010T1 (de) 2007-02-15
EP1143958B1 (en) 2007-01-31
EP1143958A2 (en) 2001-10-17
ES2281981T3 (es) 2007-10-01
JP2002524415A (ja) 2002-08-06
CA2342628C (en) 2009-07-07
WO2000013684A2 (en) 2000-03-16
US6472433B2 (en) 2002-10-29
US20010012849A1 (en) 2001-08-09
EP1143958B8 (en) 2007-05-23
DE69933049D1 (de) 2006-10-12
EP1143958A3 (en) 2002-08-21
CY1106541T1 (el) 2012-01-25
CN1391470A (zh) 2003-01-15
WO2000013684A3 (en) 2002-05-30
CA2342628A1 (en) 2000-03-16
DK1143958T3 (da) 2007-04-10
AU6026099A (en) 2000-03-27

Similar Documents

Publication Publication Date Title
PT1143958E (pt) Composição farmacêutica e utilização de rnsaid para o tratamento da inflamação.
AU713569B2 (en) Use of a r-nsaid in a protective composition for the treatment of colorectal cancer
US5981592A (en) Method and composition for treating cystic fibrosis
US6160018A (en) Prophylactic composition and method for alzheimer&#39;s Disease
US5331000A (en) Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5382591A (en) Antipyretic and analgesic methods using optically pure R-ketorolac
ES2253810T3 (es) Uso de r-aines para la prevencion de la enfermedad de alzheimer.
Michaels et al. Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors
Karavokiros et al. Flumazenil: a benzodiazepine antagonist
JP2017533956A (ja) 筋肉痛を含む病態の治療のための組合せ
ES2280196T3 (es) Utilizacion de r-acidos arilpropionicos para la preparacion de medicamentos destinados al tratamiento de enfermedades en seres humanos y animales, sobre las que se puede influir terapeuticamente mediante la inhibicion de la activacion de nf-kb.
AU2004222809B2 (en) Pharmaceutical Composition and Method for Treatment of Inflammation
MX2012000058A (es) Medicamento para uso de antiinflamatorios no esteroideos a largo plazo.
BRPI1103205A2 (pt) Composição farmacêutica oral e uso da composição farmacêutica oral
PT2848259E (pt) Formulações farmacêuticas de tiocolquicosido de libertação prolongada
BR102012029127B1 (pt) combinação farmacêutica contendo agente analgésico e agente antiespasmódico